Live feed08:00:00·54dPRReleasevia QuantisnowMBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for HypoparathyroidismByQuantisnow·Wall Street's wire, on your screen.MBX· MBX Biosciences Inc.Health Care
